Anne Brendel is a member of Goodwin’s Life Sciences Group and Healthcare practice. Anne focuses her practice on regulatory issues affecting a variety of healthcare industry clients, with a strong emphasis on telehealth. As a member of the Center for Connected Health Policy, she’s on the leading edge of changes to telehealth regulations.
Her regulatory practice is concentrated on healthcare fraud and abuse, corporate practice, privacy, consent, Medicare and Medicaid enrollment, reimbursement and billing, licensing and certification, accreditation, and compliance. Ms. Brendel assists clients with meeting reporting and payment requirements under the Medicare 60-Day Rule and filing self-disclosures under the OIG’s Self-Disclosure Protocol for potential violations involving civil monetary penalties and CMS’s Voluntary Self-Referral Disclosure Protocol for potential Stark Law violations.
She has experience responding to federal government subpoenas and civil investigative demands involving alleged fraudulent billing for professional services, lab diagnostic tests, and medications and negotiating settlements, including Corporate Integrity Agreements.
